We don't disclose AXA as a percentage of the VA business, but you should know that the VA business for us is across every major insurance company, frankly, in the world, and that we were a major, and are a major participant in active equity managers who are utilized in the VA platforms. Now, you know that what occurred in 2008, across almost all active managers, Bernstein was no different, was that there was a significant deviation of the returns, vis-a-vis benchmarks, and because it was on the negative side, that clearly caused a reaction on the part of most insurance companies to de-risk their VA product, so that the hedging costs would actually be substantially lower for them, and the balance sheet strain and the P&L effect of that would be reduced going forward. So we've seen that actual de-risking occur, including the development of products within the VA market that actually have built into them and re-risking mechanisms. Our own point of view of this is that this is a bit of a cycle. Ultimately you have to ask yourself the question is, how valuable, or how successful can a VA product be that over time only offers passive investing. I think the answer to that is sort of obvious in history. Almost always, those products move back into active management. So we probably are at a point where most insurance companies have taken action against their VA or in their VA products to reduce the significant divergence that's possible, from active management vis-a-vis the benchmark, and that moves in the future are more likely to be back into active management as opposed to more into passive. So I'm not signaling to you there's a huge opportunity next quarter, but I am saying to you, over the next few years, I think the trend is going to be positive for active managers as opposed to negative from the point of view of active versus passive. Now, as to its impact on us, since we're big players in that marketplace, you know, I think that that probably could be a net positive for us, but it also will depend on our performance.